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Background: The impact of postoperative complications on the prognosis of gastric
cancer remains controversial. This study aimed to evaluate the relationship between
postoperative complications and long-term survival in patients undergoing gastrectomy
for stage II/III gastric cancer.
Methods: Some 939 patients underwent curative gastrectomy for stage II/III gastric
cancer were identified from real-world data prospectively collected between 2013 and
2015. We divided patients according to the presence of serious complications,
specifically, Clavien-Dindo grade III or higher complications or those causing a hospital
stay of 15 days or longer.
Results: Serious complications occurred in 125 (13.3%) patients. Patients without
serious complications (64.3%) completed adjuvant chemotherapy significantly more
than patients with serious complications (37.6%; p<0.001). The 5-year overall survival
(OS) rate was 58.1% and recurrence-free survival(RFS) rate was 58.1% in patients with
serious complications, which were significantly worse than those of patients without
serious complications (73.4% and 74.7%, respectively; p<0.001 for both). In stage II,
once patients completed adjuvant chemotherapy adequately, the OS and RFS of patients
with serious complications did not differ from those without serious complications.
However, in stage III, the patients with serious complications showed a worse OS even
after completion of adequate adjuvant chemotherapy.
Conclusion: Serious complications after gastrectomy had a negative impact on the
prognosis of stage II/III gastric cancer patients. Serious complications worsen the survival
in association with inadequate adjuvant chemotherapy. Efforts to reduce serious
complications, as well as support adequate chemotherapy through properApril 2021 | Volume 11 | Article 6115101
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cancer patients.Keywords: gastric cancer, complication, chemotherapy, prognosis, real-world data (RWD)INTRODUCTION
Over a million new gastric cancer are diagnosed worldwide,
making it the fifth most common cancer and the third leading
cause of cancer death (1). Radical gastrectomy provides the only
definitive chance to cure gastric cancer (2, 3); however, patients
that undergo gastrectomy frequently experience postoperative
complications. The complication rates following gastrectomy for
gastric cancer is reported to be approximately 10–60% (4, 5),
with 1.3–12.5% of major complications (6, 7), despite recent
advances in surgical techniques and perioperative patient care.
Complications after cancer surgery have detrimental effects
on the prognosis of cancer patients, which has been shown in
colorectal cancer (8), head and neck cancer (9), and esophageal
cancer (10). Several studies have evaluated the impact of
postoperative complications on the long-term outcome of
gastric cancer patients (5, 6, 11–13). However, the prognostic
impact of complications after gastrectomy on gastric cancer
patients remains controversial. These conflicting results are
derived from the potential under-reporting of complications
and their management in retrospective studies, as well as the
selection bias of enrolling relatively physically fit patients in
prospective studies. Data from a real-world setting may
overcome these drawbacks and clarify the prognostic impact of
complications after gastrectomy.
We hypothesized that the effect of complications after
gastrectomy on the prognosis of gastric cancer patients could
be exactly evaluated with prospectively collected real-world data.
This study aimed to investigate the relationship between
postoperative complications and long‐term survival in a large
cohort of patients undergoing gastrectomy for gastric cancer
using prospectively collected real-world data.MATERIALS AND METHODS
Patients
A prospectively collected gastric cancer database consisting of
3363 patients who underwent gastrectomy from January 2013 to
December 2015 was reviewed retrospectively. A total of 1009
patients with pathologic stage II/III gastric cancer who
underwent curative gastrectomy was identified from the
database. Patients who met any of the following criteria were
excluded from the analysis: completion total gastrectomy,
gastrectomy combined with other cancer surgery, history of
preoperative chemotherapy or radiotherapy, mortality or
recurrence within 3 months of the operation, and lost to
follow-up. No patient died of complications three months after
gastrectomy. This study was approved by the Institutional2
Review Board of Severance Hospital, Yonsei University Health
System (Protocol 4-2020-0303).
Surgery
Seven surgeons performed gastrectomy for gastric cancer. Three
of them performed only open surgery, whereas the other four
surgeons performed minimally invasive surgery (MIS), including
laparoscopic and robotic surgery, as well as open surgery. MIS
was usually performed for patients with serosa-negative
advanced gastric cancer with or without limited involvement of
perigastric lymph nodes. In contrast, patients with serosa-
positive advanced gastric cancer or extensive involvement of
perigastric lymph nodes were generally considered for open
gastrectomy. The gastric resection extent (total, distal subtotal,
or proximal gastrectomy) was determined based on tumor
location. D1+ lymphadenectomy was performed for early-stage
gastric cancer and D2 lymphadenectomy was performed for
advanced gastric cancer. The reconstruction method used for
distal subtotal gastrectomy was gastroduodenostomy,
gastrojejunostomy, or Roux-en Y gastrojejunostomy. The
reconstruction method used for total gastrectomy was Roux-en
Y esophagojejunostomy and that of proximal gastrectomy was
double tract reconstruction (14). Tumor stage was defined
according to the 8th edition of American Joint Committee on
Cancer staging system (15).
Perioperative Management
At our institution, we established a “standard clinical pathway”
for patients undergoing gastrectomy. We injected prophylactic
antibiotics 15 minutes before surgery without administering
routine postoperative antibiotics. We only used postoperative
antibiotics in cases where gross bowel content contamination
occurred during surgery or when symptoms and signs of
inflammation, such as fever and leukocytosis, persisted for 3
days or more after surgery. We indwelled a urinary catheter in
the operating room after anesthesia and removed it on
postoperative day (POD) 1. Nasogastric tube was not inserted
routinely, but rather only for patients with pyloric obstruction.
Postoperative pain was primarily managed by patient-controlled
anesthesia, and non-steroidal anti-inflammatory drugs were used
for additional pain control. Intravenous antiemetics were
injected every 12 hours only on the day of operation.
Mucolytics were administered every 8 hours until POD 2 to
support pulmonary toileting. Patients started drinking water on
POD 2, having liquid diet on POD 3, and eating a soft diet on
POD 4. On POD 5, patients were recommended to be discharged
if ready.
Details of data collection and classification of postoperative
complications are described in the Supplementary Methods.April 2021 | Volume 11 | Article 611510
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After surgery, patients with pathologic stage II/III gastric cancer
were recommended to receive 5-FU-based adjuvant
chemotherapy within 4–8 weeks after surgery. Old age itself
was not a contraindication to adjuvant chemotherapy, but
chemotherapy was not performed when the patient refused it
or the patient’s performance status was poor. A majority of
adjuvant chemotherapy regimens were TS-1 monotherapy or
XELOX (capecitabine plus oxaliplatin), which were used to treat
patients with stage II or stage III disease, respectively. TS-1 (80–
120 mg per day) was administered for 4 weeks, followed by 2
weeks of rest. This 6-week regimen was repeated for eight cycles
(16). The XELOX regimen involved 3-week cycles of oral
capecitabine (1,000 mg/m2 twice daily on days 1–14 of each
cycle) plus intravenous oxaliplatin (130 mg/m2 on day 1 of each
cycle). The XELOX treatment regimen was administered for
eight cycles (17).
Follow Up
We followed up with all patients every 3 months for 1 year after
surgery, and then every 6 months thereafter. They underwent
abdomino-pelvic computed tomography (CT) scans every 6
months for 5 years after surgery. We performed an upper
endoscopy every year. Recurrence was confirmed either by
radiologic studies, such as CT, positron emission tomography,
whole-body bone scan, or endoscopic examination with biopsy,
or by surgery.
Statistical Analysis
The serious complication (SC) group consisted of patients with
Clavien-Dindo grade III or higher complications or patients with
any complications causing a hospital stay of 15 days or longer.
Patients without complications or who stayed in the hospital for
less than 15 days with Clavien-Dindo grade I/II complications
were defined as the non-serious complication (non-SC) group.
We defined the adequate adjuvant chemotherapy group as
patients who completed chemotherapy without omission or
delayed initiation, while the inadequate adjuvant chemotherapy
group as patients who omitted, delayed in initiation, or not
completed the scheduled chemotherapy. Delayed initiation in
adjuvant chemotherapy was defined as starting at 8 weeks after
surgery (18), and incompletion of adjuvant chemotherapy was
defined as discontinued treatment during the scheduled
chemotherapy cycles.
Chi-square or Fisher’s exact tests for categorical variables
and the Mann-Whitney test for continuous variables were
used. The Kaplan-Meier method was used to calculate the
overall and recurrence-free survival, whereas differences
between survival curves were assessed using the log-rank
test. The hazard ratio (HR) and two-sided 95% confidence
intervals (CI) were estimated using a Cox proportional hazards
model. A P-value less than 0.05 was considered statistically
significant. All statistical analyses were performed using SPSS
software for Windows (version 25.0; IBM Corp., Armonk, New
York, USA).Frontiers in Oncology | www.frontiersin.org 3RESULTS
Patient Characteristics
A retrospective review of prospective data revealed 1009 patients
who underwent curative gastrectomy for stage II/III gastric
cancer. After 70 patients were excluded from the analyses
(completion total gastrectomy [n=28]; combined other cancer
surgery [n=17]; history for preoperative chemotherapy or
radiotherapy [n=4]; mortality or recurrence within
postoperative 3 months [n=17]; and follow-up loss [n=4]), data
from 939 patients were included in this study.
Patient clinicopathologic characteristics are summarized in
Table 1. The median age was 60 years (interquartile range (IQR),
52–70) and most patients were male (n=591; 62.9%). The median
BMI was 22.9 (IQR 20.8–25.0) with 229 patients (24.4%)
exhibiting a BMI of 25 or higher. The 68.5% of all patients
(n=643) underwent open gastrectomy. The majority of patients
underwent subtotal gastrectomy (n=641; 68.3%). This study
consisted of 463 (49.3%) and 476 (50.7%) patients with
pathologic stage II and stage III disease, respectively.
Complications occurred in 741 out of 939 patients (78.9%), of
which the number of patients with Clavien-Dindo grade I/II or
grade III and higher was 655 (69.8%) or 86 (9.2%), respectively.
(Additional details related to postoperative complications are in
Supplementary Table S2). The non-SC group consisted of 198
patients without complications and 616 patients with
complications less than 15 days of hospital stay. The SC group
consisted of 86 patients with Clavien-Dindo grade III or higher
and 39 patients with any complications causing a hospital stay of
15 days or longer. The SC group was more likely to be
characterized by old age, male, and higher American Society of
Anesthesiology (ASA) scores than the non-SC group (P=0.001,
P=0.04, and P=0.021, respectively). The occurrence of serious
complications was associated with tumors located in the upper
body of the stomach or advanced tumor, which required total
gastrectomy and open surgery rather than MIS (Table 1).
Compared with the non-SC group, patients who stayed in the
hospital for 15 days or longer with Clavien-Dindo grade I/II
complications were significantly associated with old age, high
ASA score, open surgery, and combined operation (P=0.040,
P=0.025, P<0.001, and P=0.011, respectively; Supplementary
Table S3). The clinicopathologic characteristics of patients
with Clavien-Dindo grade I/II complications causing a hospital
stay of 15 days or longer were similar to those with Clavien-
Dindo grade III or higher complications, except for histology
(Supplementary Table S4). The median hospital stays of
patients with Clavien-Dindo grade I/II complications causing a
hospital stay of 15 days was 16 days (IQR 15–22), which was
similar to that of patients with Clavien-Dindo grade III or higher
complications (median 15; IQR 10–22). The median stay for the
non-SC group was 7 days (IQR 6–8).
Relationship Between Postoperative
Complication and Adjuvant Chemotherapy
Overall, 750 of 939 (79.9%) patients were treated with adjuvant
chemotherapy. The SC group was associated with a higher rate ofApril 2021 | Volume 11 | Article 611510
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P<0.001). The SC group also exhibited more instances of delayed
initiation, incompletion, and inadequacy of adjuvant
chemotherapy (n=8, 9.5%; n=32, 38.1%; n=78, 62.4%) than the
non-SC group (n=14, 2.1%, P=0.002; n=135, 20.3%, P<0.001;
n=291, 35.7%, P<0.001, respectively) (Table 2). Similar findings
were observed in stages II and III (Supplementary Table S5, S6),
with only marginal differences seen in the number of patients
who did not complete their chemotherapy.
The rate of omission and inadequacy of adjuvant
chemotherapy were significantly higher in Clavien-Dindo
grade I/II patients who stayed 15 days or longer in the SC
group compared to the non-SC group (Supplementary Table
S7). However, the rate of omission, delayed initiation,
incompletion and inadequacy of adjuvant chemotherapy were
similar between the Clavien-Dindo grade I/II patients who
stayed 15 days or longer and those with Clavien-Dindo grade
III or higher complications (Supplementary Table S8).
Survival Outcomes
The median follow-up duration after surgery was 52 months
(range: 7–71 months) until the cutoff date of December 31,
2018. During the follow-up period, 245 patients (26.1%) died, of
which 52 (41.6%) were from the SC group and 193 (23.7%) were
from the non-SC group. The HR for death in the SC group, as
compared with that in the non-SC group, was 1.92 (95% CI, 1.4–
2.6; P<0.001). The 5-year overall survival rate of the SC group was
58.1% (95% CI, 49.2–68.6) and that of the non-SC group was
71.3% (95% CI, 70.0–76.9; log-rank P<0.001) (Figure 1).
The number of patients that experienced a recurrence was 240
(25.6%), of which 58 (46.4%) were from the SC group and 182
(22.4%) were from the non-SC group. The HR for recurrence in
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I 153 (16.3%) 137 (16.8%) 16 (12.8%)
II 569 (60.6%) 502 (61.7%) 67 (53.6%)
III 209 (22.3%) 169 (20.8%) 40 (32.0%)
IV 8 (0.9%) 6 (0.7%) 2 (1.6%)
Operation method <0.001
Open 643 (68.5%) 534 (65.6%) 109 (87.2%)
Laparoscopy 189 (20.1%) 180 (22.1%) 9 (7.2%)
Robot 107 (11.4%) 100 (12.3%) 7 (5.6%)
Surgical procedure 0.001
STG 641 (68.3%) 573 (70.4%) 68 (54.4%)
TG 294 (31.3%) 238 (29.2%) 56 (44.8%)




<D2 105 (11.2%) 96 (11.8%) 9 (7.2%)




No 788 (83.9%) 703 (86.4%) 85 (68.0%)
Yes 151 (16.1%) 111 (13.6%) 40 (32.0%)
Histology 0.085
Differentiated 305 (32.5%) 256 (31.4%) 49 (39.2%)
Undifferentiated 634 (67.5%) 558 (68.8%) 76 (60.8%)
Tumor depth 0.043
T1 56 (6.0%) 52 (6.4%) 4 (3.2%)
T2 130 (13.8%) 116 (14.3%) 14 (11.2%)
T3 341 (36.3%) 294 (36.1%) 47 (37.6%)
T4a 399 (42.5%) 344 (42.3%) 55 (44.0%)




N0 226 (24.1%) 201 (24.7%) 25 (20.0%)
N1 187 (19.9%) 159 (19.5%) 28 (22.4%)
N2 241 (25.7%) 208 (25.6%) 33 (26.4%)
N3 285 (30.4%) 246 (30.2%) 39 (31.2%)
Pathologic stagea 0.097
II 463 (49.3%) 410 (50.4%) 53 (49.6%)
III 476 (50.7%) 404 (42.4%) 72 (57.6%)
Complication
No 198 (21.1%) 198 (24.3%) 0
Yes 741 (78.9%) 616 (75.7%) 125 (100%)
Clavien-Dindo
grade
I 363 (49.0%) 359 (58.3%) 4 (3.2%)
II 292 (39.4%) 257 (41.7%) 35 (28.0%)
III 76 (10.3%) 0 76 (60.8%)
IV 10 (1.3%) 0 10 (8.0%)SC, serious complications; IQR, interquartile range; BMI, body mass index (calculated as
weight in kilograms divided by height in meters squared); ASA, American Society of
Anesthesiology; STG, subtotal gastrectomy; TG, total gastrectomy; PG, proximal
gastrectomy.
aPathologic stages were defined in accordance with the 8th edition of American Joint
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≤8 weeks 728 (97.1%) 652 (97.9%) 76 (90.5%)




Completed 583 (77.7%) 531 (79.7%) 52 (61.9%)
Not completed 167 (22.3%) 135 (20.3%) 32 (38.1%)
Adequacy of AC 939 <0.001
Adequatea 570 (60.7%) 523 (64.3%) 47 (37.6%)
Inadequateb 369 (39.3%) 291 (35.7%) 78 (62.4%)April 2021 | Volume 11 | ArticleSC, serious complications; AC; adjuvant chemotherapy.
aAdequate AC was defined when AC was completed without omission or delayed
initiation.
bInadequate AC was defined when AC was omitted, delayed initiation, or not completed
the scheduled chemotherapy cycles.611510
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SC patients was 58.1% (95% CI, 49.0–69.0) and that in non-SC
patients was 74.7% (95% CI, 71.5–77.9; log-rank P<0.001)
(Figure 1). When we stratified the patients according to
pathologic stages, the SC group exhibited worse overall and
recurrence-free survival rates than the non-SC group for
patients with stages II and III (Supplementary Figure S1).
Survival outcomes were also compared after dividing the
patients into three groups, namely non-SC patients who
received adequate chemotherapy (n=523), SC patients who
received adequate chemotherapy (n=47), and SC patients
whose chemotherapy was inadequate (n=78). Patients who
received inadequate chemotherapy in the SC group showed
significantly worse overall and recurrence-free survival than
non-SC patients who received adequate chemotherapy (log-
rank P<0.001 for both) (Figure 2). In stage II, SC patients who
received adequate chemotherapy had similar overall andFrontiers in Oncology | www.frontiersin.org 5recurrence-free survival outcomes to those under adequate
chemotherapy in the non-SC group (log-rank P=0.495 and
P=0.936, respectively). On the contrary, in stage III, the overall
and recurrence-free survival of SC patients under adequate
chemotherapy were similar to those who did not receive
adequate chemotherapy in the SC group (log-rank P=0.426 and
P=0.551, respectively). Non-SC patients under adequate
chemotherapy had significantly higher overall survival than SC
patients who received adequate chemotherapy (log-rank
P=0.013) even though the recurrence-free survival did not differ
statistically (log-rank P=0.115) (Supplementary Figure S2).
Patients with Clavien-Dindo grade I/II complications causing
a hospital stay of 15 days or longer exhibited worse overall and
recurrence-free survival than the non-SC group (Supplementary
Figure S3). In the SC group, the overall and recurrence-free
survival of patients with Clavien-Dindo grade I/II complications
causing a hospital stay of 15 days or longer were similar to thoseA
B
FIGURE 1 | Overall (A) and recurrence-free (B) survival in patients with and without serious complications. (A) Overall survival in patients with and without serious
complications. (B) Recurrence-free survival in patients with and without serious complications.April 2021 | Volume 11 | Article 611510
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(Supplementary Figure S4).
Multivariable analyses of overall and recurrence-free survival
identified that serious complication was not an independent risk
factor among patients under adequate adjuvant chemotherapy
(HR, 1.53; 95% CI, 0.9–2.6, P=0.129 for overall survival; HR,
1.32; 95% CI, 0.8–2.3, P=0.310 for recurrence-free survival; Table
3). Stratified by stages, inadequate adjuvant chemotherapy was
not a risk factor among patients without serious complications
(HR, 1.45; 95% CI, 0.8-2.6, P=0.215; Table 4) in the multivariable
analysis of recurrence-free survival in stage II. The presence of
serious complications was a risk factor for overall survival among
patients under adjuvant chemotherapy in stage III (HR, 1.82;
95% CI, 1.0–3.3, P=0.043; Table 5).
Of the 240 patients with recurrence, there was no difference in
recurrence pattern between the two groups (Table 6). TheFrontiers in Oncology | www.frontiersin.org 6peritoneum was the most frequent initial site of recurrence in
both groups. SC group had more frequent hematogenous
metastasis (n=11, 23.9%) than the non-SC group (n=31,
16.0%), although it was not a statistically significant
difference (P=0.203).DISCUSSION
In this study, patients with serious complications demonstrated
worse survival and a higher rate of disease recurrence than
patients without serious complications after curative
gastrectomy for stage II/III gastric cancer. A majority of
patients with serious complications failed to receive adequate
adjuvant therapy. Eventually, patients who experienced serious
complicat ions combined with inadequate adjuvantA
B
FIGURE 2 | Overall (A) and recurrence-free (B) survival according to the presence of serious complications with adequacy of adjuvant chemotherapy. (A) Overall
survival according to the presence of serious complications with adequacy of adjuvant chemotherapy. (B) Recurrence-free survival according to the presence of
serious complications with adequacy of adjuvant chemotherapy.April 2021 | Volume 11 | Article 611510
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highest recurrence rates.
Randomized controlled studies have established that adjuvant
chemotherapy following gastrectomy has survival advantages
compared to gastrectomy alone (16, 17). Thus, adequate delivery
and completion of chemotherapy is necessary to obtain a survival
benefit after curative gastrectomy for stage II/III gastric cancer.
Poor survival of patients with postoperative complications after
gastrectomy for stage II/III gastric cancer cannot be considered
apart from adjuvant chemotherapy. As shown in this study, the SC
group demonstrated a higher proportion of patients who did not
receive adequate chemotherapy.
Consistent with our results, postoperative complications in
gastric cancer patients prompted failure to complete multimodalFrontiers in Oncology | www.frontiersin.org 7therapy even in a perioperative chemotherapy setting (19).
Patients are relatively tolerant of perioperative chemotherapy
because they receive chemotherapy under a relatively healthy
condition compared to a postoperative condition. Therefore, it is
difficult to determine the effect of postoperative complications on
the survival outcomes of patients who have received preoperative
chemotherapy because chemotherapy itself can affect
postoperative complications and survival outcomes. Moreover,
in the perioperative chemotherapy setting, all patients completed
preoperative chemotherapy even though postoperative
chemotherapy could be affec ted by postopera t ive
complications. However, in the adjuvant setting, patients are
affected by the effect of the complication on the whole process of
chemotherapy. Thus, adverse effect of complications onTABLE 3 | Multivariate analyses of overall and recurrence-free survival in stage II-III gastric cancer patients.
Characteristics No. of patients Overall survival Recurrence-free survival
HR 95% CI P-value HR 95% CI P-value
Age 0.029 0.536
≤60 years 471 1 1
>60 years 468 1.347 1.030–1.762 1.089 0.830–1.429
Sex 0.773 0.691
Female 348 1 1
Male 591 1.040 0.797–1.358 0.948 0.728–1.234
ASA score 0.906 0.066
I or II 722 1 1
III or IV 217 1.018 0.759–1.366 0.734 0.528–1.021
Operation method 0.097 0.443
MIS 296 1 1
Open 643 1.316 0.952–1.819 1.138 0.818–1.582
Resection extent
Distal subtotal 641 1 1
Total 294 1.066 0.716–1.588 0.753 1.300 1.000–1.689 0.050
Proximal 4 1.322 0.165–10.583 0.793 N/A N/A 0.946
Lymph node dissection 0.642 0.087
Less than D2 105 1 1
D2 834 1.126 0.683–1.854 1.713 0.925–3.169
Tumor size <0.001 <0.001
≤50 mm 543 1 1
>50 mm 396 1.682 1.292–2.189 1.849 1.414–2.417
Tumor location
Lower 483 1 1
Middle 248 1.268 0.924–1.739 0.142 0.996 0.711–1.394 0.980
Upper/Whole 208 1.257 0.930–1.701 0.137 1.152 0.741–1.792 0.529
Histology 0.925 0.821
Differentiated 305 1 1
Undifferentiated 634 1.014 0.757–1.359 0.966 0.713–1.307
LVI 0.547 0.426
(-) 369 1 1
(+) 570 1.093 0.818–1.460 1.129 0.838–1.521
SC & AC
SC (-) & adequatea AC 523 1 1
SC (+) & adequate AC 47 1.526 0.884–2.635 0.129 1.323 0.772–2.266 0.308
SC (-) & inadequateb AC 291 2.293 1.709–3.078 <0.001 1.599 1.190–2.149 0.002
SC (+) & inadequate AC 78 2.669 1.807–3.942 <0.001 2.273 1.524–3.388 <0.001
Pathologic TNM stage <0.001 <0.001
II 463 1 1
III 476 3.197 2.370–4.312 3.137 2.306–4.268April 2021 | Volume 11 | ArticleHR, hazard ratio; CI, confidence interval; ASA, American Society of Anesthesiology; MIS, minimally invasive surgery; N/A, not applicable; LVI, lymphovascular invasion; SC, Serious
complications; AC adjuvant chemotherapy.
aAdequate AC was defined when AC was completed without omission or delayed initiation.
bInadequate AC was defined when AC was omitted, delayed in initiation, or not completed the scheduled chemotherapy cycles.611510
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perioperative one.
Studies analyzed the relationship among postoperative
complications, chemotherapy, and survival outcomes
demonstrated that survival outcomes of patients with
complications who received adjuvant therapy or completed
multimodal therapy were comparable to those of patients
without complications, similar to this study. The prognostic
impact of serious complications differed according to
pathologic stage in our study. Assessing the impact of serious
complications combined with the adequacy of chemotherapy on
survival outcome is very complex. In this study, the presence of
serious complications in stage III patients resulted in
poor prognosis regardless of adequacy of chemotherapy.
Since patients tolerate better with preoperative chemotherapy
than postoperative adjuvant chemotherapy, preoperativeFrontiers in Oncology | www.frontiersin.org 8chemotherapy has a higher completion rate than postoperative
adjuvant chemotherapy. Preoperative chemotherapy does not
increase the incidence of surgical complications (19, 20).
Furthermore, the survival outcomes after preoperative
chemotherapy were similar between patients who experienced
postoperative complications and those who did not (21).
Thus, preoperative chemotherapy may be considered for
patients who are more likely to develop complications,
especially when stage III is suspected by preoperative
assessments. However, the adverse impact of serious
complications was not profound in stage II patients. If
chemotherapy was delivered adequately, even patients with
serious complications in stage II demonstrated similar survival
to those who did not experience serious complications. Thus, it is
important to treat serious complications befittingly to administer
adequate chemotherapy.TABLE 4 | Multivariate analyses of overall and recurrence-free survival in stage II gastric cancer patients.
Characteristics No. of patients Overall survival Recurrence-free survival
HR 95% CI P-value HR 95% CI P-value
Age 0.468 0.142
≤60 years 239 1 1
>60 years 224 1.222 0.711–2.102 0.656 0.373–1.152
Sex 0.508 0.651
Female 164 1 1
Male 299 1.212 0.686–2.140 0.878 0.499–1.545
ASA score 0.955 0.044
I or II 355 1 1
III or IV 108 1.017 0.565–1.830 0.468 0.224–0.981
Operation method 0.909 0.603
MIS 190 1 1
Open 273 0.967 0.543–1.722 1.168 0.650–2.099
Resection extent
Distal subtotal 343 1 1
Total 117 1.733 1.034–2.904 0.037 1.521 0.672–3.442 0.314
Proximal 3 0.974 N/A 0.974 N/A N/A 0.973
Lymph node dissection 0.534 0.256
Less than D2 80 1 1
D2 383 1.274 0.593–2.737 1.725 0.674–4.415
Tumor size 0.033 0.001
≤50 mm 328 1 1
>50 mm 135 1.724 1.043–2.848 2.346 1.393–3.954
Tumor location
Lower 236 1 1
Middle 136 0.661 0.336–1.301 0.230 0.710 0.361–1.394 0.319
Upper/Whole 91 0.997 0.412–2.415 0.995 1.732 0.944–3.176 0.076
Histology 0.484 0.845
Differentiated 163 1 1
Undifferentiated 300 1.223 0.697–2.146 1.062 0.581–1.944
LVI 0.904 0.733
(-) 263 1 1
(+) 200 0.967 0.562–1.665 1.108 0.616–1.991
SC & AC
SC (-) & adequatea AC 241 1 1
SC (+) & adequate AC 20 0.461 0.062–3.427 0.449 0.785 0.184–3.347 0.744
SC (-) & inadequateb AC 169 1.913 1.089–3.361 0.024 1.445 0.808–2.584 0.215
SC (+) & inadequate AC 33 4.471 2.238–8.933 <0.001 4.317 2.005–9.294 <0.001April 2021 | Volume 11 | ArticleHR, hazard ratio; CI, confidence interval; ASA, American Society of Anesthesiology; MIS, minimally invasive surgery; N/A, not applicable; LVI, lymphovascular invasion; SC, Serious
complications; AC adjuvant chemotherapy.
aAdequate AC was defined when AC was completed without omission or delayed initiation.
bInadequate AC was defined when AC was omitted, delayed in initiation, or not completed the scheduled chemotherapy cycles.611510
Song et al. Prognostic Impact of ComplicationsTo consider the timely treatment of complications, we
combined the length of stay and the severity of Clavien-
Dindo complication grade to define serious complications.
Most previous studies in gastric cancer used a modifiedFrontiers in Oncology | www.frontiersin.org 9Clavien-Dindo classification system, and grade III or higher
was used to express the severity of the complication (6, 22, 23).
Under this classification, many surgeons expect patients with
complications to recover from conservative care without
active treatment to avoid a high-grade complication rating.
As a result, patients stay longer in the hospital and have poor
general conditions, which is most likely adversely affects the
delivery of chemotherapy and survival outcomes even without
serious complications. Furthermore, patients remaining in the
hospital for 15 days or longer with Clavien-Dindo grade I/II
c omp l i c a t i on s showed s im i l a r c l i n i c opa tho l o g i c
characteristics as those with Clavien-Dindo grade III or
higher complications. Similar impact on the adequacy of
chemotherapy and survival outcomes was also observed.
Therefore, serious complications are more suitable in
determining patient group according to the severity of
postoperative complications.TABLE 5 | Multivariate analyses of overall and recurrence-free survival in stage III gastric cancer patients.
Characteristics No. of patients Overall survival Recurrence-free survival
HR 95% CI P-value HR 95% CI P-value
Age 0.038 0.181
≤60 years 232 1 1
>60 years 244 1.390 1.018–1.898 1.237 0.906–1.688
Sex 0.739 0.588
Female 184 1 1
Male 292 0.948 0.692–1.299 0.919 0.676–1.248
ASA score 0.810 0.273
I or II 367 1 1
III or IV 109 0.958 0.678–1.356 0.813 0.561–1.178
Operation method 0.083 0.541
MIS 106 1 1
Open 370 1.442 0.953–2.180 1.133 0.759–1.689
Resection extent
Distal subtotal 298 1 1
Total 177 0.882 0.555–1.402 0.596 1.200 0.889–1.618 0.233
Proximal 1 2.577 0.311–21.371 0.381 N/A N/A 0.949
Lymph node dissection 0.898 0.146
Less than D2 25 1 1
D2 451 1.044 0.541–2.014 1.830 0.810–4.134
Tumor size 0.001 <0.001
≤50 mm 215 1 1
>50 mm 261 1.705 1.252–2.322 1.876 1.381–2.549
Tumor location
Lower 247 1 1
Middle 112 1.516 1.055–2.179 0.025 1.153 0.784–1.695 0.469
Upper/Whole 117 1.164 0.819–1.655 0.397 1.117 0.674–1.851 0.667
Histology 0.432 0.621
Differentiated 142 1 1
Undifferentiated 334 0.876 0.628–1.220 0.916 0.648–1.295
LVI 0.610 0.391
(-) 106 1 1
(+) 370 1.100 0.763–1.586 1.175 0.813–1.700
SC & AC
SC (-) & adequatea AC 282 1 1
SC (+) & adequate AC 27 1.821 1.020–3.250 0.043 1.465 0.821–2.615 0.196
SC (-) & inadequateb AC 122 2.561 1.825–3.594 <0.001 1.622 1.153–2.282 0.005
SC (+) & inadequate AC 45 2.246 1.401–3.599 0.001 1.791 1.117–2.871 0.016April 2021 | Volume 11 | ArticleHR, hazard ratio; CI, confidence interval; ASA, American Society of Anesthesiology; MIS, minimally invasive surgery; N/A, not applicable; LVI, lymphovascular invasion; SC, Serious
complications; AC adjuvant chemotherapy.
aAdequate AC was defined when AC was completed without omission or delayed initiation.
bInadequate AC was defined when AC was omitted, delayed in initiation, or not completed the scheduled chemotherapy cycles.TABLE 6 | Comparison of initial recurrence site according to serious











Locoregional 23 (9.6%) 21 (10.8%) 2 (4.3%) 0.266
Peritoneal 104 (43.3%) 85 (43.8%) 19 (41.3%) 0.757
Hematogenous 42 (17.5%) 31 (16.0%) 11 (23.9%) 0.203
Distant lymph
node
32 (13.3%) 27 (13.9%) 5 (10.9%) 0.585
mixed 39 (16.3%) 30 (15.5%) 9 (19.6%) 0.498SC, serious complications.611510
Song et al. Prognostic Impact of ComplicationsThe impacts of postoperative complications on the long-term
survival outcomes of cancer patients are well documented (8–
10). Complication worsens the prognosis of patients with
gastrointestinal cancer, including gastric cancer. The adverse
effects of serious complications on prognosis in our study are
consistent with the previous studies (5, 11, 19, 20). The poor
prognosis of patients with serious complications was presumed
since host immunosuppression and proinflammatory cytokines
induce the growth of residual cancer cells (24, 25). In fact,
patients who experienced anastomotic leakage, intra-abdominal
infectious complications, or inflammatory complications
following gastrectomy demonstrated worse survival than those
without complications (5, 11, 26).
This study has several limitations. First, only a relatively
small number of patients with serious complications limited to
analyze the impact of the type of complications on adjuvant
chemotherapy and survival outcomes. It is necessary to identify
the effect of each type of complication on prognosis after
gastrectomy. Second, the regimens of chemotherapy used in
this study were not homogeneous, although most of patients
received either TS-1 monotherapy or XELOX. Differences in
chemotherapy regimen may influence the adequacy because
they affect patient compliance. It is difficult to assess the precise
relationship between postoperative complications and
adequacy of chemotherapy with patient prognosis. Another
possible limitation is the retrospective nature of this study. To
exactly evaluate the prognostic impact of complications
together with chemotherapy, a randomized trial would be
ideal. However, a randomized clinical trial is not always
feasible in complication-related research. Moreover, the
patient population selected by the inclusion and exclusion
criteria in a prospective study is relatively not vulnerable,
resulting in fewer postoperative complications which do not
reflect real clinical practice. Another pitfall of randomized
clinical trials is the possibility of a selection bias in which
only patients who are fit and give informed consent to
participate in the study are enrolled. Therefore, patients
enrolled in the randomized clinical trials of surgical
procedures are relatively in good general condition. As a
result, the real-world study is considered to have more
generalizability compared to randomized clinical trials.
Therefore, in this study, we used prospectively collected real-
world data which reflected real clinical practice.
Our study confirmed that serious complications after
gastrectomy had a negative impact on the prognosis of patients
with stage II/III gastric cancer through a prospectively collected
data analysis. Serious complications significantly worsened
survival outcomes when inducing inadequacy of adjuvant
chemotherapy, rather than complication themselves. Therefore,
efforts should be made to reduce serious complications as well as
support adequate chemotherapy in a timely manner through the
proper management of serious complications, which will
improve the long-term survival of patients with stage II/III
gastric cancer. In addition, perioperative chemotherapy could
be an alternative option for patients with a high risk of serious
complications, even in Eastern countries where adjuvantFrontiers in Oncology | www.frontiersin.org 10chemotherapy is a standard treatment for patients with stage
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